Item 8.01. Other Events.



On February 26, 2021, BeiGene, Ltd. ("BeiGene") announced the closing of the
collaboration and license agreement with Novartis Pharma AG ("Novartis"),
previously announced on January 11, 2021, to develop, manufacture, and
commercialize BeiGene's anti-PD-1 antibody tislelizumab in the United States,
Canada, Mexico, member countries of the European Union, United Kingdom, Norway,
Switzerland, Iceland, Liechtenstein, Russia, and Japan. The companies have
agreed to jointly develop tislelizumab in these licensed countries, with
Novartis responsible for regulatory submissions after a transition period and
for commercialization upon regulatory approvals. In addition, both companies may
conduct clinical trials globally to explore combinations of tislelizumab with
other cancer treatments, and BeiGene has an option to co-detail the product in
North America, funded in part by Novartis. The full text of this press release
is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.

   Exhibit No.           Description

       99.1              Press Release titled "BeiGene Announces Closing of

Collaboration with Novartis


                         to Develop and Commercialize Anti-PD-1 Antibody

Tislelizumab in North America,

Europe and Japan" issued on February 26, 2021.
       104               The cover page from this Current Report on Form

8-K, formatted in Inline XBRL.

--------------------------------------------------------------------------------



                                 Exhibit Index

   Exhibit No.           Description

       99.1                Press Release titled "BeiGene Announces Closing

of Collaboration with Novartis


                         to Develop and Commercialize Anti-PD-1 Antibody

Tislelizumab in North America,

Europe and Japan" issued on February 26, 2021.

       104               The cover page from this Current Report on Form

8-K, formatted in Inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses